Title | Chronic and Acute Leukemias in Adults [electronic resource] / edited by Clara D. Bloomfield |
---|---|
Imprint | Boston, MA : Springer US, 1985 |
Connect to | http://dx.doi.org/10.1007/978-1-4613-2581-9 |
Descript | XVIII, 358 p. online resource |
1. Retroviruses and Onc Genes in Human Leukemias and Lymphomas -- 1.1 Introduction -- 1.2 Onc Genes in Leukemogenesis -- 1.3 Retroviruses in Human Leukemia-Lymphoma -- 2. Study of Differentiation and Proliferation of Leukemic Cells Using Myeloid Leukemia Cell Lines -- 2.1 Introduction: Establishment of Human Myeloid Leukemia Cell Lines -- 2.2 Human Erythroleukemia Cell Lines -- 2.3 Study of Granulocyte Differentiation Using Myeloid Leukemic Cell Lines -- 2.4 Induction of Macrophage-Like Differentiation of Human Acute Myelogenous Cells -- 2.5 Genetic Analysis of Myeloid Differentiation -- 2.6 Hormonal Modulation of Leukemic Cell Growth -- 2.7 An In Vitro Model for Chemotherapy of Acute Myelogenous Leukemia -- 2.8 Conclusion -- Acknowledgements -- References -- 3. Biological Markers in Lymphoproliferative Disorders -- 3.1 Introduction -- 3.2 Immunological Markers -- 3.3 Chronic B-Cell Malignancies -- 3.4 Chronic T-Cell Malignancies -- 3.5 Cytochemistry of Acid Hydrolases -- 3.6 Chromosomes -- 3.7 Conclusions -- Acknowledgements -- References -- 4. Surface Marker Analysis of Acute Myeloblasts Leukemia -- 4.1 Introduction -- 4.2 Differentiation of Normal Myeloid Cells -- 4.3 Detection of Myeloid-Lineage Antigens by Heteroantisera -- 4.4 Production of Monoclonal Antibodies to Myeloid Cell Surface Antigens -- 4.5 Monoclonal Antibodies Reactive with Human AML Cells -- 4.6 Expression of Myeloid Differentiation Antigens on AML Cells -- 4.7 Future Directions -- References -- 5. Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features -- 5.1 Introduction -- 5.2 Clinical and Morphologic Characteristics of the FAB Classes -- 5.3 Comparison of FAB Classes of AML -- 5.4 Discussion -- References -- 6. Chemosensitivity of In Vitro Colony Forming Units as a Predictor of Response to Antileukemic Drugs -- 6.1 Introduction -- 6.2 Colony Assays -- 6.3 Quantitation of Sensitivity to Antileukemic Drugs -- 6.4 Correlations Between In Vitro Chemosensitivities of L-CFU and Clinical Response of the Patient -- 6.5 Summary -- References -- 7. Post-Remission Therapy for Acute Myelogenous Leukemia -- 7.1 Introduction -- 7.2 Role of Induction Therapy on Remission Duration -- 7.3 Role of Consolidation Therapy on Remission Duration -- 7.4 Role of Maintenance Chemotherapy in Prolonging Remissions -- 7.5 The Role of Immunotherapy in Maintenance -- 7.6 Prognostic Variables Predicting for Prolonged Remission Duration -- 7.7 Central Nervous System Leukemia -- 7.8 Bone Marrow Transplantation -- 7.9 Summary and Conclusions -- Acknowledgement -- References -- 8. The Role of Marrow Transplantation in the Treatment of Leukemia -- 8.1 Introduction -- 8.2 Donor Selection -- 8.3 Preparative Regimens -- 8.4 Techniques of Marrow Transplantation -- 8.5 Clinical Results in Acute Nonlymphoblastic Leukemia (ANL) -- 8.6 Clinical Results in Acute Lymphoblastic Leukemia (ALL) -- 8.7 Clinical Results in Chronic Granulocytic Leukemia (CGL) -- 8.8 Leukemic Recurrence After Transplantation -- 8.9 Graft-Versus-Host Disease (GVHD) -- 8.10 Infectious Complications, Including Interstitial Pneumonia -- 8.11 Other Organ Toxicities -- 8.12 Summary -- Acknowledgements -- References -- 9 Hyperleukemias in Adult Leukemia -- 9.1 Introduction -- 9.2 Acute Myelocytic Leukemia -- 9.3 Chronic Myelocytic Leukemia -- 9.4 Acute Lymphocytic Leukemia -- 10 New Developments in the Etiology, Diagnosis, Treatment and Prevention of Infectious Complications in Patients with Leukemia -- 10.1 Introduction -- 10.2 Changing Patterns of Infections -- 10.3 New Developments in Evaluation and Diagnosis -- 10.4 Developments in Antimicrobial Therapy -- 10.5 New or Evolving Syndromes in Management of Infections in the Adult Leukemic -- 10.6 Recent Developments in Adjuvant Therapy -- 10.7 Current Concepts in Infection Prevention in Acute Leukemia